Why equine gastric disease treatment is getting more specific

CURRENT FULL VERSION: A new March 9, 2026, educational article from The Horse highlights a familiar but still clinically important point in equine practice: treating gastric disease successfully means identifying what type of disease is present, then pairing drug therapy with management change. In the sponsored piece, Ben Sykes says long-term success depends not just on medication, but also on revisiting feeding practices, reducing stress, improving overall care, and repeating gastroscopy when needed to confirm healing. (thehorse.com)

That message aligns closely with the long-running shift in the field away from treating equine gastric ulcer syndrome as a single entity. The ECEIM consensus statement recommends distinguishing equine squamous gastric disease, or ESGD, from equine glandular gastric disease, or EGGD, because the two differ in pathophysiology, lesion distribution, and treatment response. The consensus also underscores that the affected region should be clearly identified when clinicians communicate findings or make treatment decisions. (edu-veterinar.ro)

Background prevalence data help explain why this remains such a common practice issue. In the consensus statement, ESGD prevalence is reported as especially high in racehorses and other performance populations, with rates rising substantially during training and competition. Review literature since then has reinforced that ESGD is primarily linked to acid exposure, while EGGD appears to involve impaired mucosal defense and is often less straightforward to resolve. (edu-veterinar.ro)

Clinical presentation adds another layer of complexity because the signs are often nonspecific. A retrospective study in Veterinary Sciences found a significant association between ulcer location and the type of signs horses showed: physical signs were more commonly linked to ESGD, while behavioral or mixed physical-behavioral signs were more often seen in horses with EGGD or mixed disease. The same study found no association between ulcer severity and clinical signs, underscoring a practical point for clinicians: neither the nature nor the apparent intensity of signs can reliably substitute for gastroscopy when trying to localize disease.

On treatment specifics, omeprazole remains the pharmacologic mainstay, and in the U.S. Boehringer Ingelheim says GASTROGARD is the only FDA-approved equine gastric ulcer treatment, labeled at 4 mg/kg for treatment and 2 mg/kg for prevention of recurrence. But the broader evidence base suggests the story is more nuanced than “ulcers equal omeprazole.” Reviews indicate treatment is usually successful in ESGD, yet outcomes are less predictable in EGGD, where longer treatment, adjunctive sucralfate, or alternative agents may be needed. (animalhealth.boehringer-ingelheim.com)

That nuance is especially important for glandular disease. A PubMed-indexed clinical study found misoprostol was superior to combined omeprazole-sucralfate for treatment of EGGD, and additional retrospective work has continued to explore how lesion type, severity, and protocol choice affect outcomes. Meanwhile, experimental data from the University of Illinois group found omeprazole outperformed sucralfate alone in a fasting-plus-NSAID injury model, supporting continued use of acid suppression as a central tool, but not necessarily a complete answer for every case. (pubmed.ncbi.nlm.nih.gov)

The research pipeline is also testing adjunctive and preventive approaches. A recent Equine Veterinary Journal trial of a nutraceutical containing lecithin, pectin, and meadowsweet did not significantly prevent recurrence of squamous or glandular lesions by gastroscopy after omeprazole treatment, although salivary biomarkers shifted in ways that may suggest mucosal effects. Separately, conference coverage from the 2024 AAEP meeting pointed to interest in long-acting injectable omeprazole and stronger acid suppression strategies, particularly for glandular disease, though those approaches still need broader validation and real-world uptake. (equimanagement.com)

Why it matters: For equine veterinarians, the clinical and communication burden is increasingly about precision. Horses with vague behavioral or performance complaints may still be funneled toward ulcer treatment, but the literature keeps reinforcing that gastroscopy is the only reliable way to confirm disease and localize lesions before choosing therapy. Emerging sign-pattern data may help clinicians think more carefully about differentials, especially when behavioral complaints raise suspicion for glandular or mixed disease, but they do not replace endoscopy. In practice, that means resisting empiric treatment where possible, setting expectations that glandular disease may be slower or less predictable to resolve, and emphasizing that management changes, such as forage access, routine stability, and stress reduction, are not optional add-ons but part of treatment itself. (thehorse.com)

What to watch: The next phase of this story is likely to center on three questions: whether lesion-specific protocols can improve EGGD outcomes, whether recurrence can be reduced after omeprazole withdrawal, and whether adjunctive products can earn a stronger evidence base rather than relying on marketing claims. Researchers will also be watching whether larger studies can validate the apparent differences in physical versus behavioral presentations between ESGD and EGGD and turn those observations into more useful clinical triage tools. For now, the safest read for practitioners is that accurate diagnosis, targeted pharmacology, and management reform remain the standard of care. (thehorse.com)